Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06044649
Other study ID # 22010705
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 15, 2023
Est. completion date March 30, 2027

Study information

Verified date November 2023
Source Rush University Medical Center
Contact John W Burns, PhD
Phone 312-942-0379
Email john_burns@rush.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Chronic musculoskeletal pain (CP) is a major public health concern. Psychosocial treatments have been shown to be efficacious when compared to largely inert control conditions, but they are characterized by modest effects on primary outcomes. One strategy to boost efficacy is to increase our understanding of treatment mediators. Studies of mediators that directly compare different treatments with each other are needed to determine which mediators are treatment-specific, which are shared across treatments, and which contribute the most to clinical outcomes. Another strategy is to identify the patient characteristics that moderate treatment responses. Research is needed that is guided by theoretical models and that tests moderators across multiple treatments. Identifying subgroups of patients more likely to respond to one or another treatment can advance precision medicine by informing a priori patient-treatment matches that can optimize treatment effects. To accomplish these goals, the authors will conduct a randomized clinical trial to compare the mediators and moderators of the clinical effects of Cognitive-Behavioral Therapy (CBT), Acceptance and Commitment Therapy (ACT), and Emotional Awareness and Expression Therapy (EAET) on adults with chronic spinal (axial) pain. Following baseline assessment of outcome variables as well as potential mediators and moderators, 460 participants will be randomized to CBT, ACT, EAET, or treatment-as-usual control (TAU). The three treatments will be conducted as individual therapy provided weekly for 8 weeks via telehealth. The researchers will conduct weekly assessments of both potential mediators and outcomes, as well as post-treatment and 6-month follow-up assessments. The goal of the study is to identify the most powerful treatment mechanisms - specific and shared -- and reveal for whom the mediator-outcome pathways are strongest.This project can increase the effects of our psychosocial chronic pain treatments by identifying the most effective treatment mechanisms and by informing patient-treatment matches that can optimize treatment effects.


Description:

Chronic musculoskeletal pain (CP) is a major public health concern. A number of psychosocial treatments have emerged in recent decades to help address this problem. These interventions have been shown to be efficacious when compared to largely inert control conditions; however, recent meta-analyses indicate that most of these treatments are characterized by modest effects on primary outcomes. This is a critical shortcoming of these otherwise promising approaches. Rather than attempting to boost efficacy only by developing new and hopefully more powerful interventions, we can also look within our already proven treatments for ways to enhance the magnitude of treatment effects. One strategy is to increase our understanding of treatment mediators. Studies of mediators that directly compare different treatments with each other are needed to determine which mediators are treatment-specific, which are shared across treatments, and which contribute the most to clinical outcomes. The findings from such research could be used to inform adaptations to existing treatment that enhance their benefits. A second strategy for increasing the beneficial effects of existing treatments is to identify the patient characteristics that moderate treatment responses. Research is needed that is guided by theoretical models and that tests moderators across multiple treatments. Identifying subgroups of patients more likely to respond to one or another treatment can advance precision medicine by informing a priori patient-treatment matches that can optimize treatment effects. To accomplish these goals, we will conduct a randomized clinical trial to compare the mediators and moderators of the clinical effects of Cognitive-Behavioral Therapy (CBT), Acceptance and Commitment Therapy (ACT), and Emotional Awareness and Expression Therapy (EAET) on adults with chronic spinal (axial) pain. Following baseline assessment of outcome variables as well as potential mediators and moderators we will randomize 460 participants to CBT, ACT, EAET, or treatment-as-usual control (TAU). The three treatments will be conducted as individual therapy provided weekly for 8 weeks via telehealth. We will conduct weekly assessments of both potential mediators and outcomes, as well as post-treatment and 6-month follow-up assessments. In addition to comparing the three treatments to each other (and TAU) for overall efficacy, we focus on two specific aims: Aim 1 is to identify mediators that are specific to treatments and those that are shared across treatments. Aim 2 is to identify baseline moderators of specific treatments and general predictors across treatments. This project can increase the effects of our psychosocial chronic pain treatments by identifying the most powerful treatment mechanisms - specific and shared -- and revealing for whom the mediator-outcome pathways are strongest. Via increased understanding of mediator and moderators, more effective pain treatment approaches can be developed, tested, and implemented.


Recruitment information / eligibility

Status Recruiting
Enrollment 460
Est. completion date March 30, 2027
Est. primary completion date September 30, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Back/neck is primary pain location (e.g., back/neck pain greater than leg pain) - Pain for at least 3 months and experienced 4 or more days/week for the past 6 months - Pain intensity last week is >= 3 (0 to 10 rating scale) - Pain interference last week is >= 3 (0 to 10 rating scale) - At least age 18 - Lives in United States (and in a state that has psychology license agreement: PSYPACT) - Fluent in English - Has personal computer/tablet and internet access - Able to attend weekly sessions - Willing to be randomized - Seeking to improve their pain-related status via a psychological therapy Exclusion Criteria: Past 2 years (treated for or having experienced): - Complex regional pain syndrome - Epilepsy/seizure disorder - Autoimmune disease - Liver disease - Cancer - Heart disease - Substance dependence or use disorder - Schizophrenia or other psychotic disorder - Bipolar disorder - Obsessive-compulsive disorder - Borderline personality disorder - Suicide attempt or suicide intention or impulse Also: - Major medical procedure scheduled within next 9 months - Applied for/ litigating for pain-related disability/worker's compensation (past year). - Major life event/stressor in past 6 months - Cognitive impairment (screener score <=4)

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Cognitive Behavioral Therapy
CBT endorses a pain management model and teaches people skills to cope with chronic pain.
Acceptance and Commitment Therapy
ACT is based on an acceptance model that seeks to decrease pain avoidance behaviors and enhance engagement in valued, adaptive activities that contribute to fewer pain-related restrictions in functioning.
Emotional Awareness and Expression Therapy
EAET advocates a pain treatment model in which pain can be substantially reduced by helping people learn that their pain is brain-based and can be substantially reduced or eliminated by decreasing fear of pain and of various emotional/interpersonal problems.
Other:
Treatment as Usual
Participants assigned to TAU will not receive any additional psychosocial treatment beyond the other treatments they were receiving before enrolling in this study.

Locations

Country Name City State
United States Rush University Medical Center Chicago Illinois
United States Wayne State University Detroit Michigan

Sponsors (2)

Lead Sponsor Collaborator
Rush University Medical Center Wayne State University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Pain Catastrophizing Scale (PCS)-short form Potential Mediator; 6-item measure of pain catastrophizing (range 0 to 4; higher scores = higher pain catastrophizing) Baseline to post-treatment and 6-month follow-up, and weekly during treatment
Other Pain Self-Efficacy Questionnaire (PSEQ) - Short Form Potential Mediator; 4-item measure of current pain self-efficacy (range 0 to 6; higher scores = higher pain self-efficacy) Baseline to post-treatment and 6-month follow-up, and weekly during treatment
Other Survey of Pain Attitudes (SOPA): Pain Control, Disability, Harm, Emotion subscales Potential Mediator; 4, 2-item measures of current pain attitudes (range 0 to 4; higher scores = more of that construct) Baseline to post-treatment and 6-month follow-up, and weekly during treatment
Other Behavioral Activation for Depression (BADS) - Short Form Potential Mediator; 9-item measure of behavioral activation for depression in the past week (range 0 to 6; higher scores = higher behavioral activation) Baseline to post-treatment and 6-month follow-up, and weekly during treatment
Other Self-Compassion Scale (SCS) - Short Form Potential Mediator; 12-item measure of situational self-compassion (range 1 to 5; higher scores = less self-compassion) Baseline to post-treatment and 6-month follow-up, and weekly during treatment
Other Chronic Pain Acceptance Questionnaire (CPAQ) Potential Mediator; 8-item measure of current chronic pain acceptance (range 0 to 6; higher scores = more chronic pain acceptance) Baseline to post-treatment and 6-month follow-up, and weekly during treatment
Other Chronic Pain Values Inventory (CPVI) Potential Mediator; 6-item measure of current values (checklist responses) Baseline to post-treatment and 6-month follow-up, and weekly during treatment
Other Emotional Approach Coping Scale (EAC) - Short Form Potential Mediator; 4-item measure of emotional approach coping (range 1 to 4; higher scores = higher emotional approach coping) Baseline to post-treatment and 6-month follow-up, and weekly during treatment
Other Emotional Breakthrough Inventory (EBI) Potential Mediator; 6-item measure of emotional breakthroughs in the past week (range 0 to 6; higher scores = more emotional breakthroughs) Baseline to post-treatment and 6-month follow-up, and weekly during treatment
Other Psychological Insight Questionnaire (PIQ) Potential Mediator; 6-item measure of psychological insight in the past week (range 0 to 5; higher scores = more psychological insight) Baseline to post-treatment and 6-month follow-up, and weekly during treatment
Other Brain and Psychological Attributions for Pain Potential Mediator; 9-item measure of current belief of brain and psychological attributions for pain (range 0 to 4; higher scores = higher belief in brain and psychological attributions for pain) Baseline to post-treatment and 6-month follow-up, and weekly during treatment
Other Pain Anxiety Symptom Scale (PASS) Potential Mediator; 4-item measure of current pain anxiety symptoms (range 0 to 5; higher scores = worse pain anxiety symptoms) Baseline to post-treatment and 6-month follow-up, and weekly during treatment
Other Adverse Events Potential Mediator; 2-item measure of adverse events in the past week and past 6 months (checklist responses) Weekly during treatment to post-treatment and 6-month follow-up
Other Working Alliance Inventory (WAI) - Patient Potential Mediator; 6-item measure of current working alliance (range 0 to 5; higher scores = better working alliance) Weekly during treatment to post-treatment for three treatment arms only
Other Working Alliance Inventory (WAI) - Therapist - Short Form Potential Mediator; 6-item measure of current working alliance (range 0 to 5; higher scores = better working alliance) Weekly during treatment to post-treatment for three treatment arms only
Other Therapist Checklist of Patient Engagement and Homework Potential Mediator; 4-item measure on current patient engagement (range 0 to 8; higher scores = more patient engagement) Weekly during treatment to post-treatment for three treatment arms only
Other Treatment Expectancy and Credibility Questionnaire Potential Mediator; 8-item measure on current treatment expectancy and credibility (range 0 to 10; higher scores = better treatment expectancy) Weekly during treatment to post-treatment for three treatment arms only
Primary Brief Pain Inventory (BPI) - Pain Severity 4-item measure of pain severity over past week (range 0 to 10; higher scores = worse pain severity) Baseline to post-treatment and 6-month follow-up, and weekly during treatment
Primary Patient-Reported Outcome Measurement Information System (PROMIS) - Pain Interference - Short Form 8a 8-item measure of pain interference over past week (range1 to 5; higher scores = more pain interference) Baseline to post-treatment and 6-month follow-up, and weekly during treatment
Secondary Patient Global Impression of Change 1-item measure of overall health change since the start of the study (range 1 to 7; higher scores = more health improvement) Weekly during treatment to post-treatment and 6-month follow-up
Secondary Patient-Reported Outcome Measurement Information System (PROMIS) - Physical Function - Short Form 10a 4-item measure of current physical function (range 1 to 5; higher scores = poorer physical function) Baseline to post-treatment and 6-month follow-up, and weekly during treatment
Secondary Patient-Reported Outcome Measurement Information System (PROMIS) - Emotional Distress - Anxiety - Short Form 4-item measure of anxiety symptoms in the past week (range 1 to 5; higher scores = more anxiety symptoms) Baseline to post-treatment and 6-month follow-up, and weekly during treatment
Secondary Patient-Reported Outcome Measurement Information System (PROMIS) - Emotional Distress - Depression - Short Form 4-item measure of depression symptoms in the past week (range 1 to 5; higher scores = more depression symptoms) Baseline to post-treatment and 6-month follow-up, and weekly during treatment
Secondary Patient Health Questionnaire - Depression 8-item measure of depression symptoms in the past week (range 0 to 3; higher scores = more depression symptoms) Baseline to post-treatment and 6-month follow-up, and weekly during treatment
Secondary Patient-Reported Outcome Measurement Information System (PROMIS) - Fatigue - Short Form 4-item measure of fatigue in the past week (range 1 to 5; higher scores = more fatigue) Baseline to post-treatment and 6-month follow-up, and weekly during treatment
Secondary Patient-Reported Outcome Measurement Information System (PROMIS) - Sleep Disturbance - Short Form 4-item measure of sleep disturbance in the past week (range 1 to 5; higher scores = more sleep disturbance) Baseline to post-treatment and 6-month follow-up, and weekly during treatment
Secondary Patient-Reported Outcome Measurement Information System (PROMIS) - Emotional Distress - Anger - Short Form 5a 5-item measure of anger in the past week (range 1 to 5; higher scores = more anger) Baseline to post-treatment and 6-month follow-up, and weekly during treatment
Secondary Positive and Negative Affect Schedule (PANAS) - Positive Affect - Short Form 5-item measure of positive affect in the past week (range 1 to 5; higher scores = more positive affectivity) Baseline to post-treatment and 6-month follow-up, and weekly during treatment
Secondary Posttraumatic Stress Disorder Checklist (PCL) - Short Form 5-item measure of trauma symptoms in the past week (range 1 to 4; higher scores = worse PTSD symptoms) Baseline to post-treatment and 6-month follow-up, and weekly during treatment
Secondary Pain Stages of Change Questionnaire (PSOCQ): Preparation and action 13-item measure on current readiness to adopt self-management for pain, Preparation and Action items only (range 1 to 5; higher scores = more ready to change) Baseline to post-treatment and 6-month follow-up, and weekly during treatment
Secondary Opioid Use 1-item measure on opioid use in past 7 days (range 1 to 7; higher scores = more days) Baseline to post-treatment and 6-month follow-up, and weekly during treatment
Secondary Employment 3-item measure on current employment (options for current status and qualitative responses) Baseline to post-treatment and 6-month follow-up
Secondary Post-Treatment Satisfaction Questionnaire 8-item measure on patient post-treatment satisfaction (range 1 to 10; higher scores = more satisfied - also included qualitative responses) Post-Treatment to 6-Month Follow-Up
Secondary Levels of Emotional Awareness Scale (LEAS) - Forms A and B 10-item measure of current emotional awareness (includes qualitative responses); responses coded for levels of emotional awareness; higher = greater awareness; Form A baseline and Form B at post-treatment Baseline
Secondary Other Pain Treatments and Health Care Use 2-item measure of health care currently, the past 6 months, and the past 4 weeks (2 items with yes/no responses and remaining range 0 to 4; higher scores = more treatment) Baseline to post-treatment and 6-month follow-up
Secondary Inventory of Interpersonal Problems (IIP) 32-item measure of current interpersonal problems (range 0 to 4; higher scores = more interpersonal problems) Baseline to post-treatment and 6-month follow-up
Secondary American College of Rheumatology (ACR) Fibromyalgia Diagnostic Criteria - 2011 8-item measure on fibromyalgia symptoms in the past week (items with yes/no responses, a checklist, and remaining range 0 to 3; higher scores = worse fibromyalgia symptoms) Baseline to post-treatment and 6-month follow-up
Secondary Psychological Flexibility Scale (PSYFlex) 6-item measure of psychological flexibility in the past week (range 0 to 5; higher scores = higher psychological flexibility) Baseline to post-treatment and 6-month follow-up
Secondary The Tobacco, Alcohol, Prescription medications, and other Substance (TAPS) Tool - Part II 9-item measure on substance use in the past week (yes/no responses); higher scores = more use Baseline to post-treatment and 6-month follow-up
Secondary Posttraumatic Stress Disorder Checklist (PCL) 20-item measure of PTSD symptoms in the past month (range 0 to 4; higher scores = worse PTSD symptoms) Baseline to post-treatment and 6-month follow-up
See also
  Status Clinical Trial Phase
Completed NCT01659073 - Using Perfusion MRI to Measure the Dynamic Changes in Neural Activation Associated With Caloric Vestibular Stimulation N/A
Recruiting NCT05914311 - Use of Dermabond in Mitigation of Spinal Cord Stimulation (SCS) Trial Lead Migration N/A
Recruiting NCT05422456 - The Turkish Version of Functional Disability Inventory
Enrolling by invitation NCT05422443 - The Turkish Version of Pain Coping Questionnaire
Completed NCT05057988 - Virtual Empowered Relief for Chronic Pain N/A
Completed NCT04385030 - Neurostimulation and Mirror Therapy in Traumatic Brachial Plexus Injury N/A
Recruiting NCT06206252 - Can Medical Cannabis Affect Opioid Use?
Completed NCT05103319 - Simultaneous Application of Ketamine and Lidocaine During an Ambulatory Infusion Therapy as a Treatment Option in Refractory Chronic Pain Conditions
Completed NCT03687762 - Back on Track to Healthy Living Study N/A
Completed NCT04171336 - Animal-assisted Therapy for Children and Adolescents With Chronic Pain N/A
Completed NCT03179475 - Targin® for Chronic Pain Management in Patients With Spinal Cord Injury Phase 4
Completed NCT03418129 - Neuromodulatory Treatments for Pain Management in TBI N/A
Completed NCT03268551 - MEMO-Medical Marijuana and Opioids Study
Recruiting NCT06204627 - TDCS* and Laterality Trainnning in Patients With Chronic Neck Pain N/A
Recruiting NCT06060028 - The Power of Touch. Non-Invasive C-Tactile Stimulation for Chronic Osteoarthritis Pain N/A
Completed NCT05496205 - A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers Phase 1
Completed NCT00983385 - Evaluation of Effectiveness and Tolerability of Tapentadol Hydrochloride in Subjects With Severe Chronic Low Back Pain Taking Either WHO Step I or Step II Analgesics or no Regular Analgesics Phase 3
Recruiting NCT05118204 - Randomized Trial of Buprenorphine Microdose Inductions During Hospitalization Phase 4
Terminated NCT03538444 - Repetitive Transcranial Magnetic Stimulation for Opiate Use Disorder N/A
Not yet recruiting NCT05812703 - Biometrics and Self-reported Health Changes in Adults Receiving Behavioral Treatments for Chronic Pain